They also noted significantly improved survival for histological Grade 2 or 3 astrocytomas with a BRAF V600E mutation compared to Grade 2 or 3 wild-type astrocytomas (95). This evidence concerns the gene BRAF and astrocytoma (excluding glioblastoma).